Acquisition advances Leica Biosystems' end-to-end anatomic pathology ecosystem, expanding integrated solutions that help laboratories move from sample to answer with speed and confidence for the clinicians and patients who depend on them

此次收购推动了徕卡生物系统端到端解剖病理生态系统的进步，扩展了集成解决方案，帮助实验室以速度和信心从样本到答案，为依赖它们的临床医生和患者提供服务。

DEER PARK, Ill.

伊利诺伊州迪尔帕克

,

，

Sept. 28, 2026

2026年9月28日

/PRNewswire/ -- Leica Biosystems, a Danaher company (the 'Company') and a global leader in digital and anatomic pathology solutions advancing precision cancer diagnostics, announced today that the Company has completed its acquisition of privately held StatLab Medical Products ('StatLab'), a leading provider of pre-analytical consumables and equipment, from Linden Capital Partners and Audax Private Equity.

/美通社/ -- 丹纳赫公司（以下简称“公司”）旗下子公司、全球数字病理与解剖病理解决方案领导者并致力于推动精准癌症诊断的徕卡生物系统（Leica Biosystems）今日宣布，公司已从林登资本合伙人（Linden Capital Partners）和奥达克斯私募股权（Audax Private Equity）手中完成对私营企业StatLab Medical Products（以下简称“StatLab”）的收购。StatLab是分析前耗材与设备的领先供应商。

For patients and their care teams, precision cancer diagnostics can provide critical information about the type and characteristics of the disease, helping inform more personalized treatment decisions..

对于患者及其照护团队，精准癌症诊断可以提供关于疾病类型和特征的关键信息，从而帮助制定更个性化的治疗决策。

Continue Reading

继续阅读

Leica Biosystems Completes Acquisition of StatLab to Bolster Delivery of More Precise, Timely Diagnostics for Cancer Patients

徕卡生物系统完成对StatLab的收购，以加强为癌症患者提供更精准、更及时的诊断服务

'We are pleased to officially welcome StatLab to Leica Biosystems, uniting StatLab's trusted portfolio and deep customer relationships with Leica Biosystems' global leadership in digital and computational pathology and AI-enabled diagnostics,' said Gustavo Perez-Fernandez, Group Executive, Danaher's Diagnostics Business, and President, Leica Biosystems.

丹纳赫诊断业务集团执行官兼徕卡生物系统公司总裁古斯塔沃·佩雷斯-费尔南德斯表示：“我们很高兴正式欢迎StatLab加入徕卡生物系统，将StatLab备受信赖的产品组合和深厚的客户关系，与徕卡生物系统在数字和计算病理学以及人工智能辅助诊断领域的全球领导地位相结合。”

'Together, we are even better positioned to help laboratories achieve the consistency, standardization and quality needed to advance precision oncology at scale. When clinicians have access to timely, high-quality diagnostic information, they are better equipped to understand each patient's cancer and determine the most appropriate care approach. Every step we take to accelerate critical cancer diagnostics helps patients get on the path to treatment faster.'.

“携手合作，我们更能帮助实验室实现规模化推进精准肿瘤学所需的一致性、标准化和质量。当临床医生能够及时获取高质量的诊断信息时，他们便能更深入地了解每位患者的癌症状况，并确定最合适的治疗方案。我们为加速关键癌症诊断所采取的每一步举措，都有助于患者更快踏上治疗之路。”

By bringing together complementary capabilities across the pathology workflow, Leica Biosystems is bolstering its comprehensive end-to-end lab portfolio, from specimen collection and preparation through advanced staining, digital imaging and AI-enabled diagnosis. This expanded offering is designed to help pathology laboratories optimize critical histology workflows, reduce variation and move from sample to answer with greater speed, consistency and confidence—supporting more efficient diagnostic workflows at a time when laboratories are facing rising case volumes, increasing complexity and ongoing staffing pressures..

通过整合病理工作流程中的互补能力，徕卡生物系统公司正在加强其全面的端到端实验室产品组合，涵盖从标本采集和制备到高级染色、数字成像以及人工智能辅助诊断的各个环节。这一扩展的产品组合旨在帮助病理实验室优化关键的组织学工作流程，减少变异，并以更快的速度、更高的一致性和更强的信心实现从样本到结果的转化——在实验室面临病例量上升、复杂性增加以及持续人员压力的背景下，支持更高效的诊断工作流程。

Ultimately, this expanded offering can help clinicians deliver more timely answers for the patients who depend on them. It also supports the continued advancement of precision cancer therapies through Leica Biosystems' work with biopharma partners, further strengthened by Danaher's connected ecosystem of innovation..

最终，这一扩展的产品组合能够帮助临床医生为依赖他们的患者提供更及时的诊断答案。同时，通过徕卡生物系统与生物医药合作伙伴的协作，并结合丹纳赫互联创新生态系统的有力支持，该方案也推动了精准癌症疗法的持续进步。

Leica Biosystems and StatLab remain focused on supporting customers with the same commitment to quality, service and partnership as the businesses come together. The transaction was completed on September 28, 2026.

随着两家公司的整合，徕卡生物系统（Leica Biosystems）和 StatLab 将继续秉持对质量、服务和合作伙伴关系的同等承诺，专注于为客户提供支持。该交易于 2026 年 9 月 28 日完成。

About Leica Biosystems

关于徕卡生物系统

Leica Biosystems is a cancer diagnostics company and a global leader in end-to-end anatomic and digital pathology solutions. The company offers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. With a broad presence across the pathology workflow from biopsy to diagnosis, Leica Biosystems is well positioned to break down the barriers between each step.

徕卡生物系统公司是一家癌症诊断企业，也是端到端解剖病理和数字病理解决方案的全球领导者。该公司为病理流程的每一步提供全面的产品组合，涵盖从样本制备和染色到成像及报告的全过程。凭借在从活检到诊断的整个病理工作流程中的广泛布局，徕卡生物系统公司处于有利地位，能够打破各环节之间的壁垒。

The company's mission of 'Advancing Cancer Diagnostics, Improving Lives' is at the heart of its corporate culture. Leica Biosystems is proud to be a Danaher Corporation subsidiary. Learn more at .

“推进癌症诊断，改善患者生活”的公司使命是其企业文化的核心。徕卡生物系统公司自豪地成为丹纳赫集团旗下的子公司。了解更多，请访问。

www.leicabiosystems.com

www.leicabiosystems.com

.

。

About Danaher

关于丹纳赫

Danaher is a leading global life sciences and diagnostics innovator, committed to accelerating the power of science and technology to improve human health. Through our connected ecosystem of industry-leading businesses, we work side by side with customers to solve their most complex scientific and clinical challenges—helping move innovations from discovery to delivery faster for patients who depend on them.

丹纳赫是全球领先的生命科学与诊断创新者，致力于加速科技力量以改善人类健康。通过我们由行业领先企业组成的互联生态系统，我们与客户携手合作，解决他们最复杂的科学和临床挑战——帮助将创新从发现到交付更快地推进，造福依赖这些创新的患者。

Powered by the Danaher Business System, our advanced science and technology and proven ability to innovate help enable faster, more accurate diagnoses and reduce the time, cost, and risk required to discover, develop, and deliver life-changing therapies. Through continuous improvement and operational excellence, our approximately 60,000 associates worldwide are focused on delivering lasting impact and improving quality of life around the world, while building a healthier, more sustainable tomorrow.

依托丹纳赫业务系统，我们凭借先进的科学技术与经证实的创新能力，助力实现更快速、更精准的诊断，并缩短发现、开发和交付变革性疗法所需的时间，降低其成本与风险。通过持续改进和卓越运营，我们全球约60,000名员工致力于产生持久影响，改善全球人们的生活质量，同时构建一个更健康、更可持续的明天。

Explore more at .

在 . 探索更多内容。

www.danaher.com

www.danaher.com

.

。

Cautionary Statement Regarding Forward-Looking Statements

关于前瞻性陈述的警示性声明

All statements other than statements of historical fact included in this communication that address activities, events or developments that the Company believes or anticipates will or may occur in the future are 'forward-looking' statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements.

本通讯中除历史事实陈述外，所有涉及本公司相信或预期将来会或可能发生的活动、事件或发展的陈述，均属于联邦证券法律意义上的“前瞻性”陈述。存在许多重要因素可能导致实际结果、发展和业务决策与这些前瞻性陈述所暗示或指出的情况存在重大差异，因此您不应过度依赖任何此类前瞻性陈述。

These factors include, among other things: the impact of the tariffs and related actions implemented by the U.S. and other countries, the impact of the Company's debt obligations on its operations and liquidity, deterioration of or instability in the global economy, the markets the Company serves and the financial markets, uncertainties with respect to the development, deployment, and use of artificial intelligence in the Company's business and products, the impact of global health crises, uncertainties relating to national laws or policies, including laws or policies to protect or promote domestic interests and/or address foreign competition, the Company's ability to successfully identify and consummate appropriate acquisitions and strategic investments, the Company's ability to integrate the businesses it acquires and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other risks relating to acquisitions, investments, strategic relationships and divestitures (in each case, including with respect to the Company's acquisition of StatLab), including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs, c.

这些因素包括但不限于：美国及其他国家实施的关税及相关行动的影响；公司债务义务对其运营和流动性的影响；全球经济、公司所服务市场以及金融市场的恶化或不稳定；与公司业务和产品中人工智能的开发、部署和使用相关的不确定性；全球健康危机的影响；与国家法律或政策相关的不确定性，包括旨在保护或促进国内利益和/或应对外国竞争的法律或政策；公司成功识别并完成适当收购和战略投资的能力；公司整合所收购业务并实现预期增长、协同效应及其他收益的能力；与收购、投资、战略关系和资产剥离相关的或有负债及其他风险（在每种情况下，包括与公司收购StatLab相关的情形），包括与过去及未来的首次公开募股（IPO）、分拆或剥离相关的税务及其他或有负债。

For more information, contact:

更多信息，请联系：

Emma Brown, Head of Communications – Leica Biosystems

艾玛·布朗，徕卡生物系统公司传播部主管

[email protected]

[email protected]

SOURCE Leica Biosystems

来源：徕卡生物系统

21

二十一

%

%

more press release views with

更多新闻稿浏览量，使用

Request a Demo

申请演示